Document:

Exhibit 10.2

 

TERMINATION AGREEMENT

 

This Termination Agreement (the “Termination Agreement”) is entered into as of December 29, 2015 (“Termination Date”), between CellSeed Inc., having its place of business at Katsura Bldg. 4F, 61, Haramachi 3-chome, Shinjuku-ku, Tokyo 162-0053 (“CELLSEED”) and Emmaus Medical, Inc., having its place of business at 21250 Hawthorne Blvd., Suite 800, Torrance, CA 90503 (“EMMAUS”).  CELLSEED and EMMAUS are hereinafter collectively referred to as the “Parties,” and respectively as the “Party.”

 

WITNESSETH:

 

WHEREAS, the Parties entered into the Joint Research and Development Agreement (the “Master Agreement”) on April 8, 2011 for research and development of the cell sheet engineering regenerative medicine products;

 

WHEREAS, the Parties entered into an Individual Agreement (the “Individual Agreement”) on April 8, 2011 pursuant to the Master Agreement, for research and development, and commercialization of CAOMECS in the United States;

 

WHEREAS, the Parties entered into an Addendum to Joint Research and Development Agreement (the “Addendum”) on August 25, 2011, in order to clarify the construction of some provisions of the Master Agreement; and,

 

WHEREAS, the Parties desire to terminate the Master Agreement, the Individual Agreement and the Addendum (collectively the “Agreements”) as more particularly set forth herein.

 

NOW, THEREFORE, in consideration of the premises and the mutual promises and undertakings set forth herein, and intending to be legally bound hereby, CELLSEED and EMMAUS do hereby agree and acknowledge as follows:

 

1.                                              All capitalized terms used herein that are not otherwise defined herein shall have the respective meanings ascribed to them in the Agreements.

 

2.                                              The Parties hereby terminate the Agreements as of the Termination Date by

 

1

 

mutual agreement.

 

3.                                              The Parties hereby acknowledge that,

 

(a)                                         EMMAUS has fully paid the aggregate amount of One Hundred and Twelve Million and Five Hundred Thousand Yen (JPY112,500,000) (USD1,500,000 at the exchange rate of USD1 to JPY75.00) (the “Fund”) for consideration for the delivery of the PACKAGE pursuant to Article 3.1 of the Individual Agreement;

 

(b)                                         EMMAUS shall not request CELLSEED to provide any further information pursuant to the Agreements.  Any future delivery of information related to CAOMECS will be covered under a separate agreement; and,

 

(c)                                          in no circumstances shall CELLSEED be required to refund the Fund to EMMAUS.

 

4.                                              To the extent not inconsistent with this Termination Agreement and except as specifically set forth as survival provisions in Article 14.3 of the Master Agreement and Article 11.4 of the Individual Agreement, neither CELLSEED nor EMMAUS shall have any further rights or obligations under the Agreements.

 

5.                                              Each Party hereby releases and forever discharges the other party, its shareholders, subsidiaries, AFFILIATEs, officers, directors, employees, attorneys, agents, representatives and assigns, past, present or future, from any and all claims, losses, obligations, suits, liens, contracts, agreements, promises, demands, debts, liabilities, costs, expenses, and damages including attorneys’ fees, and causes of action of any kind whatsoever, known or unknown, suspected or unsuspected, fixed or contingent, which each party ever had, now has or hereafter may have, related to or arising out of any provisions of the Agreements not restated in this Termination Agreement which each Party has or may have under the Agreements as of the Termination Date.

 

6.                                              This Termination Agreement and each of the terms hereof shall be kept confidential, and each Party agrees not to disclose to any third party any of the terms hereof except to its accountants or attorneys or as may be required by

 

2

 

laws or regulations.

 

7.                                              This Termination Agreement shall be governed by and construed in accordance with the laws of the State of New York, exclusive of the choice of law rules thereof.

 

IN WITNESS WHEREOF, the Parties have caused this Termination Agreement, through their duly appointed and authorized representatives, to be executed in duplicate as of the date executed by both Parties.

 

	
CellSeed Inc.
    	
 
    	
Emmaus Medical, Inc.
    
	
 
    	
 
    	
 
    
	
 Signed 
    	
/s/ Setsuko Hashimoto
    	
 
    	
 Signed 
    	
_/s/ Yutaka Niihara
    
	
 Name Setsuko   Hashimoto
    	
 
    	
 Name Yutaka Niihara
    
	
 Title   President and CEO
    	
 
    	
 Title   Chairman and CEO
    
	
 Date
    	
December 29, 2015
    	
 
    	
 Date
    	
December 29, 2015
    
							

 

3wndw_ex101.htm

  
EXHIBIT 10.1
 
Redacted Copy
 
CONFIDENTIAL PORTIONS OF THIS AGREEMENT HAVE BEEN OMITTED AND FILED SEPARATELY. THE REDACTED TERMS HAVE BEEN MARKED AT THE APPROPRIATE PLACE WITH FOUR ASTERISKS ****.
 
Modification No. **** to CRADA No. ****
 
	Facility Operator:
	 
	Alliance for Sustainable Energy, LLC ("Alliance")

	 
	 
	National Renewable Energy Laboratory

	 
	 
	 

	Participant:
	 
	SolarWindow Technologies, Inc.

	 
	 
	 

	Period of Performance:
	 
	**** through ****

	 
	 
	This modification adds $**** to the agreement and extends the period of performance for ****.

 
Except as stated herein, all terms and conditions of the Cooperative Research and Development Agreement shall remain in full force and effect without change. In the event of any conflict between the terms of the subject Agreement and this Modification, the provisions of this Modification shall take precedence.
 
ARTICLE II, "Joint Work Statement" is modified to include Appendix A "Joint Work Statement for Modification No ****," which is attached hereto and incorporated by reference.
 
ARTICLE III, "Term, Funding, and Costs," Paragraph A, is modified to reflect a new completion date of ****. It is hereby acknowledged and agreed that existing work under CRADA Modification **** may continue to be performed by Contractor until ****.
 
ARTICLE III, "Term, Funding, and Costs," Paragraph B, is modified to add a Participant funds-in contribution of $****. Total contributions, including those previously provided under this Agreement, are as follows:
 
	 	 
	Prior Contributions
	 
	Modification No. ****
	 
	Total

	Participant In-Kind Contribution:
	 
	$****
	 
	$****
	 
	$****

	Participant Funds-In Contribution:
	 
	$****
	 
	$****
	 
	$****

	Government In-Kind Contribution:
	 
	$****
	 
	$****
	 
	$****

	CRADA TOTAL VALUE
	 
	$****
	 
	$****
	 
	$****

 
APPENDIX A-Joint Work Statement: The attached Appendix A "Joint Work Statement for Modification No. ****" is hereby added to the Agreement.
 
The parties have indicated their acceptance of this Modification No. **** to Agreement No. **** between SolarWindow Technologies, Inc. and Alliance, operator of the National Renewable Energy Laboratory by signature below. This Modification shall not be effective until approved by the U.S. Department of Energy.
 
	 
	1

	

	 

 
Redacted Copy
 
CONFIDENTIAL PORTIONS OF THIS AGREEMENT HAVE BEEN OMITTED AND FILED SEPARATELY. THE REDACTED TERMS HAVE BEEN MARKED AT THE APPROPRIATE PLACE WITH FOUR ASTERISKS ****.
    

	Accepted:
	 
	Accepted:

	SolarWindow Technologies, Inc.
	 
	Alliance for Sustainable Energy, LLC.

	 
	 
	 
	 
	 

	By: 
	/s/ John A. Conklin
	 
	By:
	/s/ Bobi Garrett

	Name:
	John A. Conklin 
	 
	Name:
	Bobi Garrett

	Title: 
	President & CEO
	 
	Title:
	Deputy Laboratory Director Strategic Programs & Partnerships

	  
	 
	 
	 
	 

	Date: December 21, 2015 
	 
	Date: December 22, 2015

	 
	 
	 
	 
	 

	 
	 
	 
	 

	 
	 
	 
	 
	
	Accepted:
	 
	 
	 
	
	DOE Approval, if scope and/or dollar increase  
	 
	 
	
	 
	 
	 
	 
	 

	By:
	/s/ David Lighthall
	 
	 
	 

	Name:
	David Lighthall 
	 
	 
	
	Title: 
	Contracting Officer 
	 
	 
	 

	 
	 
	 
	 
	 

	Date: December 28, 2015  
	 
	 
	 

 
	 
	2

	

	 

 
Redacted Copy
 
CONFIDENTIAL PORTIONS OF THIS AGREEMENT HAVE BEEN OMITTED AND FILED SEPARATELY. THE REDACTED TERMS HAVE BEEN MARKED AT THE APPROPRIATE PLACE WITH FOUR ASTERISKS ****.

 
National Renewable Energy Laboratory
 
Cooperative Research and Development Agreement
 
Appendix A—Joint Work Statement- 
Modification No. ****
 
CRADA # ****
 
Title: Commercialization of SolarWindow Technologies, Inc. Organic Photovoltaic "OPV" based Transparent Electricity-Generating ****
 
Abstract of CRADA work:
 
SolarWindow Technologies, Inc. (SWT) is preparing, over the **** (beginning ****), to commercialize the company's OPV-based SolarWindowTM transparent electricity-generating **** for building-integrated photovoltaic (BIPV), and glass and flexible substrate applications. SWT and NREL will work jointly towards commercialization by ****, ****; ****, ****, ****, and **** of the SolarWindowTM technology. Furthermore, SWT and NREL will identify and perform appropriate **** in preparation for obtaining all **** required for product commercialization. 
 
In parallel with the progress towards commercialization with the ****, SWT and NREL will also ****, and **** to further improve ****. This **** includes ****. Enhancing **** includes the ****.
 
Participant Name and Address:
 
SolarWindow Technologies, Inc. 
10632 Little Patuxent Parkway, Suite 406
Columbia, MD 21044
 
Participant Type
 
	Foreign
	 ̈

		 

	University
	 ̈

		 

	Small Business
	x

		 

	Large Business
	 ̈

		 

	State & Local Government
	 ̈

		 

	Not-for-Profit
	 ̈

 
Schedule
 
The Period of Performance for this effort will continue until ****.
 
	 
	3

	

	 

 
Redacted Copy
 
CONFIDENTIAL PORTIONS OF THIS AGREEMENT HAVE BEEN OMITTED AND FILED SEPARATELY. THE REDACTED TERMS HAVE BEEN MARKED AT THE APPROPRIATE PLACE WITH FOUR ASTERISKS ****.
 
Purpose
 
Work under this CRADA will be directed towards ****, ****, and **** of Participant's BIPV technology.
 
Task Descriptions and Estimated Completion Dates
 
**** Areas of Work:
 
	 
	·
	****:

 
		o 	****

			
		o 	****, ****, ****, ****, etc.

 

	 
	·
	****

 
		o 	****, ****, ****

			
		o 	****, ****, **** (****)

			
		o 	****, ****, ****

			
		o 	****

 
	 
	·
	****

 
		o 	****/****/****

			
		o 	****

			
		o 	****

 
	 
	·
	****:

 
		o 	****

			
		o 	New ****

			
		o 	Alternative ****

			
		o 	****Alternatives:

 
	 
	·
	****, etc.

	 
	·
	****

 
		o 	**** Alternatives:

 
	 
	·
	****

 
		o 	****:

 
	 
	·
	****

	 
	·
	****

 
	 
	·
	****

    
		o 	****

 
		o 	****:

    
	 
	·
	****

	 
	·
	****

 
	 
	·
	**** Development:

    
		o 	****

			
		o 	****

 
	 
	·
	Support for ****

 
		o 	****, ****, ****, etc.

 
	 
	·
	Support for ****

 
		o 	****

 
	 
	·
	Goal: ****

 
		o 	Maintain ****

			
		o 	****

			
		o 	****

			
		o 	****

			
		o 	****

			
		o 	****

			
		o 	****

 
	 
	4

	

	 

 
Redacted Copy
 
CONFIDENTIAL PORTIONS OF THIS AGREEMENT HAVE BEEN OMITTED AND FILED SEPARATELY. THE REDACTED TERMS HAVE BEEN MARKED AT THE APPROPRIATE PLACE WITH FOUR ASTERISKS ****.
 
	 
	·
	SolarWindow Module ****

 
		o 	**** and ****

			
		o 	****

 
	 
	·
	**** Access

 
	 
	·
	****

    
	 
	·
	****

 
	 
	·
	****

 
	 
	·
	****

 
	 
	·
	Building ****

    
		o 	**** on glass of SolarWindow applied ****

 
**** Areas of Work (Primary Focus):
 
	 
	·
	Support to ****of ****& ****

 
		o 	Develop and meet ****

			
		o 	**** round of ****

 
	 
	·
	****

 
	 
	·
	**** Development:

 
		o 	****

			
		o 	****, ****

			
		o 	**** Modules from ****

			
		o 	**** and ****

			
		o 	**** and **** configurations

 
	 
	·
	**** Integration (SolarWindow ****)

 
		o 	**** in ****

 
	 
	·
	****

	 
	·
	****

 
		o 	Demonstration of ****

 
	 
	·
	****

 
		o 	**** Measurement

 
	 
	·
	****

	 
	·
	Impact on ****

 
		o 	In-situ Deploymen****t

 
	 
	·
	****

	 
	·
	****

	 
	·
	Data ****

	 
	·
	Data ****

 
	 
	 
	 

	 
	·
	SolarWindowTM **** as a **** Conditions

    
		o 	The **** of this **** is to accurately **** SolarWindowTM module **** under ****

 
	 
	·
	****

	 
	·
	****

	 
	·
	****

	 
	·
	****

	 
	·
	****

	 
	·
	****

 
	 
	5

	

	 

 
Redacted Copy
 
CONFIDENTIAL PORTIONS OF THIS AGREEMENT HAVE BEEN OMITTED AND FILED SEPARATELY. THE REDACTED TERMS HAVE BEEN MARKED AT THE APPROPRIATE PLACE WITH FOUR ASTERISKS ****.
 
Year 2 Areas of Work (Secondary Focus):
 
	 
	·
	**** Devices:

 
		o 	****

			
		o 	****

			
		o 	****

 
	 
	·
	**** Process Development:

 
		o 	****

 
Funding Table
 
	Estimated Costs
	 
	NREL
Shared Resources
	 
	Participant 
Shared Resources
	 
	Participant 
Funds In
	 
	Totals

	Year ****
	 
	$****
	 
	$****
	 
	$****
	 
	$****

	Year ****
	 
	$****
	 
	$****
	 
	$****
	 
	$****

	Year ****
	 
	$****
	 
	$****
	 
	$****
	 
	$****

	TOTALS
	 
	$****
	 
	$****
	 
	$****
	 
	$****

	Fed Admin Charge on Funds-in
	 
	****
	 
	****
	 
	****
	 
	****

 
DOE Mission Area to benefit from this CRADA:
 
	Energy	x

		
	Environmental Quality	 ̈

		
	Science	 ̈

		
	Other, name: 	 ̈

 
CRADA benefit to DOE, Participant, and US Taxpayer:
 
The technology developed under this CRADA would enable the Participant to **** and **** with **** and ****. In that the technology **** under the CRADA would facilitate the **** and **** of ****, it is aligned with the objectives of the DOE National Solar Energy Programs. The CRADA will benefit the U.S. taxpayer by promoting the adoption of clean energy technology and contributing to the growth and viability U.S. **** industry.
 
DOE Program Manager: Lidija Sekaric, 202-306-5434
 
CRADA format is Modular CRADA. If other, such as multilab or USIC, identify: N/A .
 
Special Considerations
 
Background Intellectual Property: 
 
No  ̈ Yes x If yes, list: See attached Appendix B
 
	 
	6

	

	 

 
Redacted Copy
 
CONFIDENTIAL PORTIONS OF THIS AGREEMENT HAVE BEEN OMITTED AND FILED SEPARATELY. THE REDACTED TERMS HAVE BEEN MARKED AT THE APPROPRIATE PLACE WITH FOUR ASTERISKS ****.
 
Is Participant interested in licensing BIP at this time: No  ̈   Yes  ̈ x To be determined
 
If yes, identify any known special issues with a potential license (i.e., BIP still in ROI stage, or already exclusively licensed, or has broader applications than scope of CRADA, or in contention right now with another partner. If none, write "NONE.").
 
Are human or animal subjects to be used as part of this CRADA? 
 
No x Yes  ̈
 
Have all necessary ES&H and quality (NEPA) reviews been completed? 
 
Yes x   No  ̈(if not, explain) 
 
Are there any organizational or personal conflicts of interest associated with this CRADA?
 
No x   Yes  ̈(explain)
 
NREL maintains on file signed COI certificates for each employee with a substantial role in this CRADA.
 
Will export controlled information be produced? 
 
No x   Yes  ̈(if yes, identify)
 
Fairness of Opportunity requirements have been satisfied by: 
 
x Participant approached laboratory
 
 ̈ Participant responded to FedBizOpps announcement
 
 ̈ Participant was contacted by laboratory after or during broad public announcement or solicitation
 
For 100% funds-in CRADAs, the Participant has been notified of other types of technology transfer agreements, such as Work for Others.
 
 ̈ Yes    ̈ No   x N/A
 
Did the Participant require any substantive changes to the Modular CRADA or any changes to double-underlined language?
 
No x Yes  ̈ If yes, attach copies of the proposed modified articles. If substantively altered, attach Participant's US Competitiveness justification.
 
Additional Special Considerations: NONE
 
 
7

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00253-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00253-of-00352.parquet"}]]